Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director
May 28 2020 - 12:05PM
- Notes the resignation of Emmanuel Babeau as of May 22,
2020
- Coopts Gilles Schnepp for the remainder of Emmanuel Babeau’s
term of office
PARIS – May 22, 2020 – At its
meeting held on May 22, 2020, the Board of Directors duly noted the
resignation of Emmanuel Babeau and decided, after consultation of
the Appointments and Governance Committee, to coopt Gilles Schnepp
as Independent Director for the remainder of Emmanuel Babeau’s term
of office (expiring at the end of the Annual Shareholders’ Meeting
held in 2022 to approve the financial statements for the fiscal
year ending December 31, 2021). The cooptation of Gilles Schnepp
will be subject to ratification by the next Shareholders’ Meeting
of Sanofi, on April 28, 2021.
Gilles Schnepp has also been appointed as a
member of the Audit Committee.
A graduate of HEC in 1981, Gilles Schnepp began
his career at Merrill Lynch in 1983 before joining Legrand in 1989
where he held several positions before becoming Deputy Chief
Executive Officer in 2001, Chief Executive Officer in 2004 and
Chairman and Chief Executive Officer in 2006. Since 2018, he has
been Chairman of the Board of Directors
Gilles Schnepp has also been a member of the
Board of Directors of Saint Gobain since 2009 and Vice-Chairman of
the Supervisory Board of PSA since 2019.
Gilles Schnepp thus brings to the Board his
skills in financial matters and his experience in managing
international groups.
The entire Board of Directors thanked Emmanuel
Babeau for his very substantial and active participation in the
meetings of the Board and of the Audit Committee of which he was a
member.
The Board of Directors has 16 members, including
11 who are deemed independent and two Directors representing
employees.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Media Relations Contact Quentin Vivant Tel.: +33
(0)1 53 77 46 46 mr@sanofi.com |
Investor
Relations Contact Félix Lauscher Tel.: +33 (0)1 53 77 45
45 ir@sanofi.com |
About Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare
Sanofi (EU:SAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Sep 2023 to Sep 2024